Proteins and Peptides
23 December 2014
Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection22 December 2014
Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment for Von Willebrand Disease22 December 2014
Sobi’s Xiapex receives positive opinion by CHMP for the treatment of Peyronie’s disease20 December 2014
Jazz Pharmaceuticals Receives FDA Approval For Intravenous Administration Of Erwinaze® (asparaginase Erwinia chrysanthemi)19 December 2014
Tresiba® receives positive opinion from CHMP for treatment of children with diabetes18 December 2014
D-Pharm Achieves Primary End-point in Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With tPA18 December 2014
First Patient Treated in Mapi Pharma’s Phase IIa Clinical Trial of GA Depot for Relapsing Remitting Multiple Sclerosis (RRMS)17 December 2014
Bayer Submits Biologics License Application for BAY 81-8973 for the Treatment of Hemophilia A in Adults and Children17 December 2014
Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim16 December 2014
Capstone Therapeutics Announces Phase 1b/2a Study Results for AEM-28 Showing Safety and Biomarker Efficacy Signals16 December 2014
Stemline Therapeutics Initiates SL-401 Clinical Trial in Four Rare Myeloproliferative Neoplasms16 December 2014
Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder15 December 2014
Synageva BioPharma Announces Active Investigational New Drug Application For SBC-103 For The Treatment Of Mucopolysaccharidosis IIIB15 December 2014
Ultragenyx Announces Initiation of Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 715 December 2014
Sophiris Bio Reports Administrative Interim Analysis for the “PLUS-1” Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia13 December 2014
Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium11 December 2014
ArmaGen Announces FDA Acceptance of IND Application for AGT-182 for the Treatment of Hunter SyndromeNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports